Patents Examined by Shanon A. Foley
  • Patent number: 12011477
    Abstract: The present invention relates to a process for producing an immunogenic live attenuated Chikungunya virus, as well as pharmaceutical compositions comprising the same.
    Type: Grant
    Filed: September 26, 2022
    Date of Patent: June 18, 2024
    Assignee: Valneva SE
    Inventors: Andrea Fritzer, Andreas Meinke, Urban Lundberg, Mario Nebenführ, Jürgen Heindl-Wruss, Robert Schlegl, Arnaud Leon
  • Patent number: 12005113
    Abstract: The present invention is directed to novel nucleotide and amino acid sequences of Porcine Epidemic Diarrhea Virus (“PEDV”), including novel genotypes thereof, all of which are useful in the preparation of vaccines for treating and preventing diseases in swine and other animals. Vaccines provided according to the practice of the invention are effective against multiple swine PEDV genotypes and isolates. Diagnostic and therapeutic polyclonal and monoclonal antibodies are also a feature of the present invention, as are infectious clones useful in the propagation of the virus and in the preparation of vaccines. Particularly important aspects of the invention include polynucleotide constructs that replicate in tissue culture and in host swine. The invention also provides for novel full length PEDV genomes that can replicate efficiently in host animals and tissue culture.
    Type: Grant
    Filed: September 15, 2020
    Date of Patent: June 11, 2024
    Assignees: Zoetis Services LLC, Iowa State University Research Foundation, Inc.
    Inventors: Jianqiang Zhang, Qi Chen, Phillip Gauger, Darin Madson, John Morgan Hardham, Meggan Bandrick, Jay Gregory Calvert, James Richard Thompson, Mira Ivanova Stoeva, Walter Valdez
  • Patent number: 11998596
    Abstract: The present invention relates to African swine fever virus (ASFV) peptides and/or polypeptides as well as immunogenic fragments thereof, corresponding encoding AFSV oligonucleotides and/or polynucleotides as well as immunogenic fragments thereof, immunogenic compositions, vaccines and uses thereof.
    Type: Grant
    Filed: December 16, 2022
    Date of Patent: June 4, 2024
    Inventors: Veljko Nikolin, Egbert Siegfried Mundt, Fernando Rodriguez Gonzalez, Laia Bosch Camos, Javier Alonso Collado Miguens
  • Patent number: 11993633
    Abstract: In some embodiments, the present invention provides respiratory syncytial virus (RSV) F proteins, polypeptides and protein complexes that comprise one or more cross-links to stabilize the protein, polypeptide or protein complex in its pre-fusion conformation. In some embodiments the present invention provides RSV F proteins, polypeptides and protein complexes comprising one or more mutations to facilitate such cross-linking. In some embodiments the present invention provides compositions comprising such proteins, polypeptides or protein complexes, including vaccine compositions, and methods of making and using the same.
    Type: Grant
    Filed: May 27, 2021
    Date of Patent: May 28, 2024
    Inventors: Christopher Patrick Marshall, Jason Scott McLellan, Peter Joseph Alff, Claudio Bertuccioli, Roberto Mariani
  • Patent number: 11987601
    Abstract: Nucleic acids encoding norovirus VP1 fusion proteins and VLPs comprising the norovirus VP1 fusion proteins are provided. Methods for norovirus VP1 fusion protein and norovirus VLP production in plants are also described. The VP1 fusion protein comprises, a first sequence encoding an S domain derived from a first norovirus strain, and a second sequence encoding a P domain derived from a second norovirus strain.
    Type: Grant
    Filed: May 3, 2022
    Date of Patent: May 21, 2024
    Assignee: ARAMIS BIOTECHNOLOGIES INC.
    Inventors: Pierre-Olivier Lavoie, Marc-Andre D'Aoust
  • Patent number: 11988665
    Abstract: Certain aspects of the present disclosure generally relate to systems and methods for determining viruses. For instance, some aspects are directed to systems and methods for determining viruses using a partitioning system. Within the partitioning system, the virus may partition into one or more phases. In some cases, a virus-binding moiety facilitates partitioning of the virus. The phases may be assayed to determine the virus based on, e.g., quantitative or qualitative assessments of the distribution of virus-binding and/or signaling moieties. The virus-binding moiety may be attached to particles that may form a complex around a virus. The complex may be detectable without a signaling moiety (e.g., as a color change) in some embodiments. In some cases, more than one virus may be determined. For example, a virus-binding moiety may substantially alter the partitioning behavior of one virus or complex, relative to another, by being selective for the first virus.
    Type: Grant
    Filed: February 26, 2021
    Date of Patent: May 21, 2024
    Assignee: Analiza, Inc.
    Inventors: Arnon Chait, Boris Y. Zaslavsky
  • Patent number: 11981707
    Abstract: Disclosed are Respiratory Syncytial Virus (RSV) antigens including a recombinant RSV F protein stabilized in a prefusion conformation. Also disclosed are nucleic acids encoding the antigens and methods of producing the antigens. Methods for generating an immune response in a subject are also disclosed. In some embodiments, the method is a method for treating or preventing a RSV infection in a subject by administering a therapeutically effective amount of the antigen to the subject.
    Type: Grant
    Filed: September 11, 2023
    Date of Patent: May 14, 2024
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Peter D. Kwong, Barney S. Graham, Jason S. McLellan, Jeffrey Boyington, Lei Chen, Man Chen, Gwo-Yu Chuang, Ivelin Stefanov Georgiev, Jason Gorman, Michael Gordon Joyce, Masaru Kanekiyo, Gilad Ofek, Marie Pancera, Mallika Sastry, Cinque Soto, Sanjay Srivatsan, Guillaume Stewart-Jones, Yongping Yang, Baoshan Zhang, Tongqing Zhou
  • Patent number: 11957746
    Abstract: The present invention in particular relates to a method of producing an immunogenic composition exhibiting reduced virucidal activity, as well as to the immunogenic composition and uses thereof, wherein the method in particular comprises the steps of: (a) providing a mixture with a first liquid and a recombinant protein, (b) concentrating the recombinant protein in the mixture by removing a portion of the first liquid from the mixture, and (c) processing the solution resulting from step (b) by continuous diafiltration.
    Type: Grant
    Filed: March 25, 2019
    Date of Patent: April 16, 2024
    Inventors: Leigh Wilmes, Matthew Coons, Amanda Brown, Michael Johannes Gassel, Francois-Xavier Orveillon, Katharina Hedwig Toepfer, Elida Bautista, Kathy Schlesinger
  • Patent number: 11952611
    Abstract: Disclosed herein are methods and systems for rapid detection of antibiotic resistance of a microorganism in a sample. A modified recombinant phage is also disclosed which comprises an indicator gene in the late gene region. The specificity of infectious agents allows a specific microorganism to be targeted, and an indicator signal may be amplified to optimize assay sensitivity.
    Type: Grant
    Filed: July 3, 2018
    Date of Patent: April 9, 2024
    Assignee: Laboratory Corporation of America Holdings
    Inventors: Minh Mindy Bao Nguyen, Dwight L. Anderson, Jose S. Gil, Stephen E. Erickson, Matthew J. Brown
  • Patent number: 11951164
    Abstract: A method is described for producing a vaccine from a neutered pathogenic source. The neutered pathogenic source may be a SARS-COV-2 virus that is neutered with a defined dose of UV-C light. The neutered SARS-COV-2 viral vaccine is administered through an inhalation pump.
    Type: Grant
    Filed: November 22, 2022
    Date of Patent: April 9, 2024
    Assignee: PERUMALA HOLDINGS, LLC
    Inventor: Madhavan Pisharodi
  • Patent number: 11931410
    Abstract: Provided is a SARS-CoV-2 mRNA vaccine, and the preparation method and use thereof. The present invention provides an mRNA molecule capable of encoding a target polypeptide, wherein the target polypeptide comprises an NTD-RBD natural domain in the Spike (S) protein of SARS-CoV-2, and wherein the NTD-RBD natural domain comprises an NTD fragment and an RBD fragment, the NTD fragment and the RBD fragment being linked together via a natural amino acid sequence derived from the S protein as a linker. The present invention provides an mRNA encoding a NTD-RBD natural domain in the Spike protein of SARS-CoV-2, which achieves an immune effect against SARS-CoV-2 mutant strains and is widely applicable.
    Type: Grant
    Filed: April 29, 2022
    Date of Patent: March 19, 2024
    Assignee: SHENZHEN RHEGEN BIOTECHNOLOGY CO., LTD.
    Inventor: Yong Hu
  • Patent number: 11926657
    Abstract: Binding molecules, including bispecific antibodies that include at least two anti-influenza binding domains are disclosed, including binding molecules having a first binding domain that specifically binds influenza A virus and a second binding domain that specifically binds influenza B virus.
    Type: Grant
    Filed: November 11, 2022
    Date of Patent: March 12, 2024
    Assignee: MEDIMMUNE, LLC
    Inventors: Nicole Kallewaard-Lelay, Qing Zhu, Godfrey Jonah Rainey, Cuihua Gao, Srinath Kasturirangan, Changshou Gao
  • Patent number: 11926649
    Abstract: The present invention provides mutant RSV F molecules, such as those that can be, or are stabilized, in a pre-fusion conformation by the introduction of one or more DT cross-links. The present invention also provides methods of making such mutant RSV F molecules, compositions comprising such mutant RSV F molecules, and methods of use of such mutant RSV F molecules, for example in vaccination methods, therapeutic methods, and antibody production methods.
    Type: Grant
    Filed: February 9, 2022
    Date of Patent: March 12, 2024
    Inventors: Christopher Marshall, Mark Yondola, Roberto Mariani, Aaron Zomback, Sonal Gidwani
  • Patent number: 11918643
    Abstract: The present invention is directed to a nucleic acid suitable for use in treatment or prophylaxis of an infection with a coronavirus, preferably with a Coronavirus SARS-CoV-2, or a disorder related to such an infection, preferably COVID-19. The present invention is also directed to compositions, polypeptides, and vaccines. The compositions and vaccines preferably comprise at least one of said nucleic acid sequences, preferably nucleic acid sequences in association a lipid nanoparticle (LNP). The invention is also directed to first and second medical uses of the nucleic acid, the composition, the polypeptide, the combination, the vaccine, and the kit, and to methods of treating or preventing a coronavirus infection, preferably a Coronavirus infection.
    Type: Grant
    Filed: December 21, 2021
    Date of Patent: March 5, 2024
    Assignees: CUREVAC SE, GLAXOSMITHKLINE BIOLOGICALS SA
    Inventors: Nicole Roth, Diego Chaves Moreno, Hans Wolfgang Große, Dominik Vahrenhorst, Susanne Rauch
  • Patent number: 11918645
    Abstract: A pharmaceutical composition comprising at least two peptides of from 15 to 60 amino acids in length, selected from peptides comprising a sequence of at least 15 contiguous amino acids of one of the sequences shown in SEQ ID NOs: 1 to 4 or of a sequence having at least 80% identity to one of the sequences shown in SEQ ID NOs: to 4, wherein each peptide comprises at least one CD8+ T-cell epitope and/or at least one CD4+ T-cell epitope and wherein each peptide elicits a response in peripheral blood mononuclear cells (PBMC) from at least one chronically infected HBV individual in an 10 in vitroassay.
    Type: Grant
    Filed: July 9, 2022
    Date of Patent: March 5, 2024
    Assignee: Altimmune UK Limited
    Inventors: Bertrand Victor Gilbert Georges, Carlton Bradley Brown
  • Patent number: 11918646
    Abstract: Described herein are dry immunogenic compositions and methods of freezing aluminum-containing vaccines such that when converted into a dried powder, the dry composition can be readily administered without loss of activity. Also described are methods of intranasal administering dry immunogenic compositions comprising antigens and aluminum adjuvants.
    Type: Grant
    Filed: December 11, 2018
    Date of Patent: March 5, 2024
    Assignee: Board of Regents, The University of Texas System
    Inventors: Zhengrong Cui, Sachin G. Thakkar
  • Patent number: 11911455
    Abstract: The nucleic acid sequences provided by the present invention comprises sequence HPV16-AVLS1 and sequence HPV16-AVLC1 in a 1:1 ratio; and sequence HPV18-AVLS1 and sequence HPV18-AVLC1 in a 1:1 ratio; the sequence AVLS1 and the sequence AVLC1 comprise two concatenated E6 proteins, two LI short peptides, two L2 short peptides, two concatenated E7 proteins, one PADRE sequence, and one adjuvant sequence respectively; the N-terminal of sequence AVLS1 carries a mouse IgK secretion peptide sequence; the N-terminal of sequence AVLC1 carries a ubiquitin sequence. The nucleic acid sequences provided by the present invention can not only induce high titer antibodies against E6/E7, but also elicit a high level of functional cellular immune, demonstrating excellent preventive and therapeutic effects against tumors related to HPV.
    Type: Grant
    Filed: August 25, 2023
    Date of Patent: February 27, 2024
    Assignee: Beijing Aeonvital Biomedicine Research Co., Ltd.
    Inventors: Xiujun Zhang, Lei Liu, Jianming Tang
  • Patent number: 11911453
    Abstract: The disclosure relates to respiratory syncytial virus (RSV) ribonucleic acid (RNA) vaccines as well as methods of using the vaccines and compositions comprising the vaccines. The vaccine can be formulated in a lipid nanoparticle.
    Type: Grant
    Filed: January 28, 2019
    Date of Patent: February 27, 2024
    Assignee: ModernaTX, Inc.
    Inventors: Giuseppe Ciaramella, Kapil Bahl, Amy Espeseth, Andrew J. Bett, Pedro Cejas, Lan Zhang, Christine Shaw
  • Patent number: 11911460
    Abstract: A lipid delivery system, a virus-like structure (VLS) vaccine constructed therefrom, and a lipid particle capable of encapsulating an mRNA molecule encoding a SARS-CoV-2-specific antigen are provided. After the lipid particle encapsulates an mRNA molecule encoding a SARS-CoV-2 antigen, a SARS-CoV-2 S1 antigen protein can be embedded on a surface of an envelope structure of the lipid under specific buffer conditions to produce a VLS vaccine with an antigen-encoding mRNA molecule encapsulated inside and an outer membrane presenting a required viral antigen protein. The vaccine has a superior specific antibody-inducing ability to a SARS-CoV-2 mRNA vaccine and a polypeptide vaccine, can maintain a long-lasting high antibody level, and can also exhibit excellent immune binding abilities for the emerging different variants.
    Type: Grant
    Filed: August 1, 2023
    Date of Patent: February 27, 2024
    Assignees: Weirui Biotechnology (Kunming) Co., LTD., Shandong Weigao Litong Biological Products Co., Ltd.
    Inventors: Qihan Li, Kaili Ma, Yanmei Li, Jingjing Zhang, Lichun Wang, Changyong Mu, Xiaowu Peng, Yanrui Su, Chang'e Liu, Liping He, Lin Feng, Dongxiu Gao, An Wang, Hongbing Li, Gang Xu, Fuyun He, Lichun Zheng, Hongkun Yi
  • Patent number: 11911454
    Abstract: The invention provides isolated polynucleotide molecules that comprise a DNA sequence encoding an infectious RNA sequence encoding a genetically-modified North American PRRS virus, methods to make it and related polypeptides, polynucleotides, and various components. Vaccines comprising the genetically modified virus and polynucleotides and a diagnostic kit to distinguish between naturally infected and vaccinated animals are also provided.
    Type: Grant
    Filed: June 6, 2022
    Date of Patent: February 27, 2024
    Assignee: Zoetis Services LLC
    Inventors: Jay Gregory Calvert, Robert G. Ankenbauer, Jacqueline Gayle Marx, Douglas S. Pearce, Marcia L. Keith